Connect with us:
  • |#lymsm
I'm interested in

  • All subtypes
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Hodgkin Lymphoma
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Rare Lymphoma

    Rare Lymphoma

    Rare Lymphoma
    • Burkitt Lymphoma
    • High-grade B-cell lymphoma, NOS
    • Primary CNS lymphoma
    • Waldenström Macroglobulinemia
    • Hairy Cell Leukemia
  • T-Cell Lymphoma

    T-Cell Lymphoma

    T-Cell Lymphoma
    • EBV+ T-cell lymphomas
    • Enteropathy-associated T-cell lymphoma
    • Follicular T-cell related lymphoma
    • Indolent T-cell lymphoproliferative disorders (LPD) of the GI tract
    • Lymphoma, T-Cell, Cutaneous
    • PTCL
    • Precursor T-lymphoblastic lymphoma/leukemia

Interested in specific subtype?

Filter what you see here

  • Medical Information
  • Licenses
  • Trials
  • About
  • Sign Up
83 articles |Clear filters Filter
Keyword search

Topic

Categories

Congress Coverage

Clear filters

83 articles|Clear filters

HL

ASCO 2018 | Final analysis of the AHL2011 LYSA study

Sara Valente , Jun 21, 2018 , Expert Opinion

CLL/SLL

ASCO 2018 | Ibrutinib plus venetoclax shows promising efficacy in CLL

Sara Valente , Jun 12, 2018 , Expert Opinion

WM

ASCO 2018 | Acalabrutinib monotherapy demonstrated good efficacy in WM

Sara Valente , Jun 12, 2018

FL

ASCO 2018 | Phase III RELEVANCE study compares R2 to R-Chemo

Sara Valente , Jun 12, 2018 , Expert Opinion

DLBCL

ASCO 2018 | Durable responses seen in large B-cell lymphoma patients treated with Axi-Cel

Sara Valente , Jun 11, 2018

CLL/SLL

William Wierda | ASCO 2018 | Ibrutinib and venetoclax combination for first-line CLL: CAPTIVATE phase II trial

Sara Valente , Jun 8, 2018

English & Spanish

DLBCL

Raul Cordoba | ASCO 2018 | Tailoring therapy for aged patients with aggressive lymphoma

Sara Valente Natasha Fort , Jun 8, 2018

HL

Joseph Connors | ASCO 2018 | Risk-adapted treatment strategies for advanced-stage HL

Sara Valente , Jun 8, 2018

FL

Nathan Fowler | ASCO 2018 | Key findings of the phase III RELEVANCE trial in FL

Nathan Fowler , Jun 8, 2018

CLL/SLL

Susan O'Brien | ASCO 2018 | What is the role of chemo-immunotherapy in CLL?

Susan O'Brien , Jun 8, 2018

  • 1
  • 2
  • 3
  • 4
  • ...
  • 9

Professional society

The European Lymphoma Institute is comprised of a network of top European specialists in the field of lymphoma who are dedicated to research, training and education. Together they look to define strategies to analyse and characterize lymphoma and its common diagnostic procedures and therapeutic standards, as well as to facilitate clinical and fundamental research. This all results in the advancement of lymphoma research and it guarantees equal access for all patients to the best possible care.


Our partners


Our supporters

Platinum
Silver
Silver
Silver
Bronze
Bronze
Contributor
  • Terms and conditions
  • Cookie policy
  • Privacy policy
  • Newsletter

© 2019 Lymphoma Hub

All content on this site is intended for healthcare professionals only.
If you are a patient or carer, please visit the Lymphoma Coalition.